Management of High Grade Dysplasia patients
Cancer Alliance | National | ||
---|---|---|---|
Number of High Grade Dysplasia patients in audit | 101 | 1120 | |
Cancer Alliance | National | ||
Method of Diagnosis | |||
– First diagnosis confirmed by second pathologist | N/A | 68.0% | 90.0% |
Treatment planning | |||
– HGD plan discussed at MDT | N/A | 87.1% | 93.0% |
– Treatment plan for active treatment | N/A | 93.8% | 82.0% |
First treatment | |||
– Endoscopic therapy (such as endoscopic resection) | N/A | 92.5% | 78.0% |
– Surveillance | N/A | 2.5% | 11.0% |
NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.
Management of oesophago-gastric cancer patients
Organisation | National | ||
---|---|---|---|
Number of oesophago-gastric (OG) cancer patients in audit | 137 | 19,865 | |
Case ascertainment for OG cancer (%) | 75-84% | ||
Method of Diagnosis | |||
– Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations |
11 | 8.2% | 13.1% |
– Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
Pre-treatment staging of cancer | |||
– Patients having staging CT scan recorded | 108 | 78.8% | 94.0% |
Treatment planning | |||
– Patients having a plan for curative treatment | 42 | 30.7% | 37.2% |
– Patients having a plan for non-curative treatment | 95 | 69.3% | 62.8% |
– Patients with non-curative plans having chemotherapy or radiotherapy | 51 | 53.7% | 34.7% |